Top

Cancer Chemotherapy and Pharmacology

Published in:

01-12-2018 | Short Communication

Enhancing 5-fluorouracil efficacy through suppression of PKM2 in colorectal cancer cells

Authors: Yong Cao, Yan Lin, Dongxu Wang, Di Pan, Ying Zhang, Yu Jin, Changqing Zheng

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2018

Abstract

Purpose

Cancer cells alter regular metabolic pathways in order to sustain rapid proliferation. One example of metabolic remodeling in cancerous tissue is the upregulation of pyruvate kinase isoenzyme M2 (PKM2), which is involved in aerobic glycolysis. Indeed, PKM2 has previously been identified as a tumor biomarker and as a potential target for cancer therapy. Here, the role of PKM2 in the anticancer efficacy of 5-fluorouracil (5-FU) was evaluated in colorectal cancer (CRC).

Methods

HCT116, SW480 and HT-29 cells were used by transfection with lentiviral vectors expressing short hairpin RNA (shRNA) against PKM2. In response to 5-FU treatment, cellular proliferation was examined, the levels of ATP/ADP ratio were monitored, the intracellular accumulation of 5-FU was measured, and intracellular levels of phosphoenolpyruvate (PEP), pyruvate and lactate were evaluated by using liquid chromatography–mass spectrometry (LC–MS). A CRC subcutaneous tumor model was performed to investigate the effect of PKM2 inhibition on 5-FU efficacy in vivo.

Results

Suppression of PKM2 resulted in changes in glucose metabolism, leading to decreased synthesis of adenosine triphosphate (ATP). Reduced levels of ATP/ADP ratio resulted in the intracellular accumulation of 5-FU, consequently enhancing the therapeutic efficacy of this drug in several CRC cell lines. Furthermore, the enhanced efficacy of 5-FU by simultaneous inhibition of PKM2 was demonstrated in an in vivo HCT116 CRC model.

Conclusion

We show that the combination treatment showed superior anticancer efficacy as compared to 5-FU alone. These findings suggest that targeting PKM2 can increase the efficacy of chemotherapy, potentially providing a new approach for improving the outcome of chemotherapy in patients with CRC.

Available only for authorised users

Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29. https://doi.org/10.3322/caac.20138 CrossRefPubMed

Favoriti P, Carbone G, Greco M, Pirozzi F, Pirozzi RE, Corcione F (2016) Worldwide burden of colorectal cancer: a review. Updates Surg 68(1):7–11. https://doi.org/10.1007/s13304-016-0359-y CrossRefPubMed

Peters GJ, van Triest B, Backus HH, Kuiper CM, van der Wilt CL, Pinedo HM (2000) Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. Eur J Cancer 36(7):916–924CrossRef

Lee JJ, Beumer JH, Chu E (2016) Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol. https://doi.org/10.1007/s00280-016-3054-2 CrossRefPubMedPubMedCentral

Cui R, Shi XY (2015) Expression of pyruvate kinase M2 in human colorectal cancer and its prognostic value. Int J Clin Exp Pathol 8(9):11393–11399PubMedPubMedCentral

Liang J, Cao R, Wang X, Zhang Y, Wang P, Gao H, Li C, Yang F, Zeng R, Wei P, Li D, Li W, Yang W (2017) Mitochondrial PKM2 regulates oxidative stress-induced apoptosis by stabilizing Bcl2. Cell Res 27(3):329–351. https://doi.org/10.1038/cr.2016.159 CrossRefPubMed

Chaneton B, Hillmann P, Zheng L, Martin AC, Maddocks OD, Chokkathukalam A, Coyle JE, Jankevics A, Holding FP, Vousden KH, Frezza C, O’Reilly M, Gottlieb E (2012) Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 491(7424):458–462. https://doi.org/10.1038/nature11540 CrossRefPubMedPubMedCentral

Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452(7184):230–233. https://doi.org/10.1038/nature06734 CrossRefPubMed

Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC (2008) Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452(7184):181–186. https://doi.org/10.1038/nature06667 CrossRefPubMed

10.

Ao R, Guan L, Wang Y, Wang JN (2017) Effects of PKM2 gene silencing on the proliferation and apoptosis of colorectal cancer LS-147T and SW620 cells. Cellular Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 42 (5):1769–1778. https://doi.org/10.1159/000479456 CrossRef

11.

Liang F, Li Q, Li X, Li Z, Gong Z, Deng H, Xiang B, Zhou M, Li X, Li G, Zeng Z, Xiong W (2016) TSC22D2 interacts with PKM2 and inhibits cell growth in colorectal cancer. Int J Oncol 49(3):1046–1056. https://doi.org/10.3892/ijo.2016.3599 CrossRefPubMed

12.

Yan XL, Zhang XB, Ao R, Guan L (2017) Effects of shRNA-mediated silencing of PKM2 gene on aerobic glycolysis, cell migration, cell invasion, and apoptosis in colorectal cancer cells. J Cell Biochem 118(12):4792–4803. https://doi.org/10.1002/jcb.26148 CrossRefPubMed

13.

Cortés-Cros M, Hemmerlin C, Ferretti S, Zhang J, Gounarides JS, Yin H, Muller A, Haberkorn A, Chene P, Sellers WR, Hofmann F (2013) M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proc Natl Acad Sci USA 110(2):489–494. https://doi.org/10.1073/pnas.1212780110 CrossRefPubMed

14.

Velimezi G, Liontos M, Vougas K, Roumeliotis T, Bartkova J, Sideridou M, Dereli-Oz A, Kocylowski M, Pateras IS, Evangelou K, Kotsinas A, Orsolic I, Bursac S, Cokaric-Brdovcak M, Zoumpourlis V, Kletsas D, Papafotiou G, Klinakis A, Volarevic S, Gu W, Bartek J, Halazonetis TD, Gorgoulis VG (2013) Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer. Nat Cell Biol 15(8):967–977. https://doi.org/10.1038/ncb2795 CrossRefPubMed

15.

Zhang L, Scorsone K, Woodfield SE, Zage PE (2015) Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition. Cancer Chemother Pharmacol 76(5):977–987. https://doi.org/10.1007/s00280-015-2871-z CrossRefPubMed

16.

Maddocks OD, Berkers CR, Mason SM, Zheng L, Blyth K, Gottlieb E, Vousden KH (2013) Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 493(7433):542–546. https://doi.org/10.1038/nature11743 CrossRefPubMed

17.

Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2(1):48–58. https://doi.org/10.1038/nrc706 CrossRefPubMed

18.

Garnier-Suillerot A, Marbeuf-Gueye C, Salerno M, Loetchutinat C, Fokt I, Krawczyk M, Kowalczyk T, Priebe W (2001) Analysis of drug transport kinetics in multidrug-resistant cells: implications for drug action. Curr Med Chem 8(1):51–64CrossRef

19.

He J, Xie G, Tong J, Peng Y, Huang H, Li J, Wang N, Liang H (2014) Overexpression of microRNA-122 re-sensitizes 5-FU-resistant colon cancer cells to 5-FU through the inhibition of PKM2 in vitro and in vivo. Cell Biochem Biophys 70(2):1343–1350. https://doi.org/10.1007/s12013-014-0062-x CrossRefPubMed

20.

Lin Y, Lv F, Liu F, Guo X, Fan Y, Gu F, Gu J, Fu L (2015) High expression of pyruvate kinase M2 is associated with chemosensitivity to epirubicin and 5-fluorouracil in breast cancer. J Cancer 6(11):1130–1139. https://doi.org/10.7150/jca.12719 CrossRefPubMedPubMedCentral

Title: Enhancing 5-fluorouracil efficacy through suppression of PKM2 in colorectal cancer cells
Authors: Yong Cao
Yan Lin
Dongxu Wang
Di Pan
Ying Zhang
Yu Jin
Changqing Zheng
Publication date: 01-12-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3676-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2018

Autophagy modulation: a prudent approach in cancer treatment?

Comment on: Yohshino et al.: combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6). Cancer Chemother Pharmacol (2017) 80:1239–1247

Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine–erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial)

Lactobacillus supplementation prevents cisplatin-induced cardiotoxicity possibly by inflammation inhibition

Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-KrasG12D/+;Tp53R172H/+ (KPC) mice, a genetically engineered model of pancreatic cancer

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer